Overview

A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To examine the safety and tolerance of three doses of oral vesnarinone in HIV-infected patients with CD4 count > 300 cells/mm3.
Phase:
Phase 1
Details
Lead Sponsor:
Otsuka America Pharmaceutical
Treatments:
Vesnarinone